{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T10:36:39Z","timestamp":1789814199337,"version":"4.0.1"},"reference-count":147,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1053\/j.seminoncol.2013.07.007","type":"journal-article","created":{"date-parts":[[2013,10,14]],"date-time":"2013-10-14T22:46:10Z","timestamp":1381790770000},"page":"634-651","source":"Crossref","is-referenced-by-count":35,"title":["Novel Agents for Multiple Myeloma to Overcome Resistance in Phase III Clinical Trials"],"prefix":"10.1053","volume":"40","author":[{"given":"Robert Z.","family":"Orlowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"26","key":"10.1053\/j.seminoncol.2013.07.007_bib1","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1053\/j.seminoncol.2013.07.007_bib2","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1053\/j.seminoncol.2013.07.007_bib3","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1200\/JCO.2006.10.5460","article-title":"Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression","volume":"25","author":"Orlowski","year":"2007","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1053\/j.seminoncol.2013.07.007_bib4","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"San Miguel","year":"2008","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1053\/j.seminoncol.2013.07.007_bib5","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","article-title":"Antitumor activity of thalidomide in refractory multiple myeloma","volume":"341","author":"Singhal","year":"1999","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1053\/j.seminoncol.2013.07.007_bib6","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1200\/JCO.2005.03.0221","article-title":"Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group","volume":"24","author":"Rajkumar","year":"2006","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1053\/j.seminoncol.2013.07.007_bib7","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2007.14.1853","article-title":"Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma","volume":"26","author":"Rajkumar","year":"2008","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1053\/j.seminoncol.2013.07.007_bib8","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa070596","article-title":"Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America","volume":"357","author":"Weber","year":"2007","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1053\/j.seminoncol.2013.07.007_bib9","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1053\/j.seminoncol.2013.07.007_bib10","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1182\/blood-2012-05-425934","article-title":"A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma","volume":"120","author":"Siegel","year":"2012","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2013.07.007_bib11","doi-asserted-by":"crossref","unstructured":"Vij R, Richardson PGG, Jagannath S, et al. Pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): outcomes in pts refractory to lenalidomide (LEN) and\/or bortezomib (BORT). J Clin Oncol. 2012;30(Suppl):abstr 8016","DOI":"10.1200\/jco.2012.30.15_suppl.8016"},{"issue":"1","key":"10.1053\/j.seminoncol.2013.07.007_bib12","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol"},{"issue":"30","key":"10.1053\/j.seminoncol.2013.07.007_bib13","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.1200\/JCO.2009.27.9158","article-title":"Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial","volume":"28","author":"Harousseau","year":"2010","journal-title":"J Clin Oncol"},{"issue":"9758","key":"10.1053\/j.seminoncol.2013.07.007_bib14","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/S0140-6736(10)61424-9","volume":"376","author":"Cavo","year":"2010","journal-title":"Lancet"},{"issue":"22","key":"10.1053\/j.seminoncol.2013.07.007_bib15","doi-asserted-by":"crossref","first-page":"5752","DOI":"10.1182\/blood-2011-05-355081","article-title":"Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma","volume":"118","author":"Moreau","year":"2011","journal-title":"Blood"},{"issue":"20","key":"10.1053\/j.seminoncol.2013.07.007_bib16","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1200\/JCO.2011.37.4918","volume":"30","author":"Garderet","year":"2012","journal-title":"J Clin Oncol"},{"issue":"34","key":"10.1053\/j.seminoncol.2013.07.007_bib17","doi-asserted-by":"crossref","first-page":"5713","DOI":"10.1200\/JCO.2009.22.2679","article-title":"Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed\/refractory multiple myeloma","volume":"27","author":"Richardson","year":"2009","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1053\/j.seminoncol.2013.07.007_bib18","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1182\/blood-2010-02-268862","article-title":"Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma","volume":"116","author":"Richardson","year":"2010","journal-title":"Blood"},{"issue":"9","key":"10.1053\/j.seminoncol.2013.07.007_bib19","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1182\/blood-2012-04-422683","article-title":"A phase 1\/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma","volume":"120","author":"Jakubowiak","year":"2012","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2013.07.007_bib20","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-12-3352","article-title":"Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma","author":"Niesvizky","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"21","key":"10.1053\/j.seminoncol.2013.07.007_bib21","first-page":"727","article-title":"MM-005: a phase 1, multicenter, open-label, dose-escalation study to determine the maximum tolerated dose for the combination of pomalidomide, bortezomib, and low-dose dexamethasone in subjects with relapsed or refractory multiple myeloma","volume":"120","author":"Richardson","year":"2012","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"21","key":"10.1053\/j.seminoncol.2013.07.007_bib22","first-page":"74","article-title":"A multi-center phase I\/II trial of carfilzomib and pomalidomide with dexamethasone (Car-Pom-d) in patients with relapsed\/refractory multiple myeloma","volume":"120","author":"Shah","year":"2012","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"5","key":"10.1053\/j.seminoncol.2013.07.007_bib23","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminoncol.2013.07.007_bib24","doi-asserted-by":"crossref","first-page":"270","DOI":"10.3324\/haematol.13782","article-title":"Expected long-term survival of patients diagnosed with multiple myeloma in 2006-2010","volume":"94","author":"Brenner","year":"2009","journal-title":"Haematologica"},{"issue":"7","key":"10.1053\/j.seminoncol.2013.07.007_bib25","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.2009.25.6081","article-title":"Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences","volume":"28","author":"Barlogie","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1053\/j.seminoncol.2013.07.007_bib26","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/leu.2012.160","article-title":"Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured?","volume":"27","author":"Usmani","year":"2013","journal-title":"Leukemia"},{"issue":"4","key":"10.1053\/j.seminoncol.2013.07.007_bib27","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1200\/JCO.2011.37.8919","article-title":"The 39th David A. Karnofsky Lecture: bench-to-bedside translation of targeted therapies in multiple myeloma","volume":"30","author":"Anderson","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2013.07.007_bib28","doi-asserted-by":"crossref","first-page":"916479","DOI":"10.1155\/2012\/916479","article-title":"Curability of multiple myeloma","volume":"2012","author":"Alexanian","year":"2012","journal-title":"Bone Marrow Res"},{"issue":"14","key":"10.1053\/j.seminoncol.2013.07.007_bib29","doi-asserted-by":"crossref","first-page":"3731","DOI":"10.1158\/1078-0432.CCR-11-2859","article-title":"Cure models as a useful statistical tool for analyzing survival","volume":"18","author":"Othus","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1053\/j.seminoncol.2013.07.007_bib30","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1158\/1535-7163.MCT-11-0433","article-title":"Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma","volume":"10","author":"Hideshima","year":"2011","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"10.1053\/j.seminoncol.2013.07.007_bib31","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/nrclinonc.2012.15","article-title":"Latest advances and current challenges in the treatment of multiple myeloma","volume":"9","author":"Mahindra","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"10.1053\/j.seminoncol.2013.07.007_bib32","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/ajh.1174","article-title":"Histone deacetylase inhibitors increase p21(WAF1) and induce apoptosis of human myeloma cell lines independent of decreased IL-6 receptor expression","volume":"68","author":"Lavelle","year":"2001","journal-title":"Am J Hematol"},{"issue":"10","key":"10.1053\/j.seminoncol.2013.07.007_bib33","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1182\/blood-2002-11-3514","article-title":"Molecular sequelae of histone deacetylase inhibition in human malignant B cells","volume":"101","author":"Mitsiades","year":"2003","journal-title":"Blood"},{"issue":"7","key":"10.1053\/j.seminoncol.2013.07.007_bib34","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1182\/blood-2003-01-0233","article-title":"NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma","volume":"102","author":"Catley","year":"2003","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminoncol.2013.07.007_bib35","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1073\/pnas.2536759100","article-title":"Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications","volume":"101","author":"Mitsiades","year":"2004","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"11","key":"10.1053\/j.seminoncol.2013.07.007_bib36","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.1158\/1078-0432.CCR-03-0561","article-title":"Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors","volume":"10","author":"Pei","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1053\/j.seminoncol.2013.07.007_bib37","doi-asserted-by":"crossref","first-page":"3773","DOI":"10.1158\/0008-5472.CAN-05-2961","article-title":"Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells","volume":"66","author":"Nawrocki","year":"2006","journal-title":"Cancer Res"},{"issue":"24","key":"10.1053\/j.seminoncol.2013.07.007_bib38","doi-asserted-by":"crossref","first-page":"8567","DOI":"10.1073\/pnas.0503221102","article-title":"Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma","volume":"102","author":"Hideshima","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"16","key":"10.1053\/j.seminoncol.2013.07.007_bib39","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1182\/blood-2011-10-386789","article-title":"Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma","volume":"120","author":"Kuhn","year":"2012","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminoncol.2013.07.007_bib40","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1080\/10428190701817258","article-title":"Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma","volume":"49","author":"Richardson","year":"2008","journal-title":"Leuk Lymphoma"},{"issue":"16","key":"10.1053\/j.seminoncol.2013.07.007_bib41","doi-asserted-by":"crossref","first-page":"5250","DOI":"10.1158\/1078-0432.CCR-08-2850","article-title":"Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma","volume":"15","author":"Badros","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1053\/j.seminoncol.2013.07.007_bib42","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.clml.2012.07.007","article-title":"Phase I trial of vorinostat combined with bortezomib for the treatment of relapsing and\/or refractory multiple myeloma","volume":"12","author":"Weber","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"21","key":"10.1053\/j.seminoncol.2013.07.007_bib43","first-page":"480","article-title":"Vantage 095: vorinostat in combination with bortezomib in salvage multiple myeloma patients: final study results of a global phase 2b trial","volume":"118","author":"Siegel","year":"2011","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"21","key":"10.1053\/j.seminoncol.2013.07.007_bib44","first-page":"811","article-title":"Vantage 088: vorinostat in combination with bortezomib in patients with relapsed\/refractory multiple myeloma: results of a global, randomized phase 3 trial","volume":"118","author":"Dimopoulos","year":"2011","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"10","key":"10.1053\/j.seminoncol.2013.07.007_bib45","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2006-04-016055","article-title":"Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells","volume":"108","author":"Catley","year":"2006","journal-title":"Blood"},{"issue":"11","key":"10.1053\/j.seminoncol.2013.07.007_bib46","doi-asserted-by":"crossref","first-page":"5781","DOI":"10.1158\/0008-5472.CAN-05-4186","article-title":"The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance","volume":"66","author":"Maiso","year":"2006","journal-title":"Cancer Res"},{"issue":"5","key":"10.1053\/j.seminoncol.2013.07.007_bib47","doi-asserted-by":"crossref","first-page":"794","DOI":"10.3324\/haematol.2009.015495","article-title":"In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma","volume":"95","author":"Ocio","year":"2010","journal-title":"Haematologica"},{"issue":"3","key":"10.1053\/j.seminoncol.2013.07.007_bib48","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.leukres.2010.06.026","article-title":"The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo","volume":"35","author":"Sanchez","year":"2011","journal-title":"Leuk Res"},{"issue":"9","key":"10.1053\/j.seminoncol.2013.07.007_bib49","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.3109\/10428194.2012.661175","article-title":"Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed\/refractory multiple myeloma","volume":"53","author":"Wolf","year":"2012","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"10.1053\/j.seminoncol.2013.07.007_bib50","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1159\/000286447","article-title":"The oral histone deacetylase inhibitor LBH589 is a potential and promising therapeutic agent in multiple myeloma after at least two lines of chemotherapy including bortezomib or lenalidomide","volume":"33","author":"Schmitt","year":"2010","journal-title":"Onkologie"},{"issue":"Suppl","key":"10.1053\/j.seminoncol.2013.07.007_bib51","article-title":"A phase lb study of oral panobinostat and IV bortezomib in relapsed or relapsed and refractory multiple myeloma","volume":"29","author":"San-Miguel","year":"2011","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"10.1053\/j.seminoncol.2013.07.007_bib52","article-title":"Phase III study of panobinostat with bortezomib and dexamethasone in patients with relapsed multiple myeloma (PANORAMA 1)","volume":"30","author":"San-Miguel","year":"2012","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1053\/j.seminoncol.2013.07.007_bib53","first-page":"3976","article-title":"Update on a phase III study of panobinostat with bortezomib and dexamethasone in patients with relapsed multiple myeloma: PANORAMA 1","volume":"118","author":"San-Miguel","year":"2011","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"22","key":"10.1053\/j.seminoncol.2013.07.007_bib54","doi-asserted-by":"crossref","first-page":"4420","DOI":"10.1200\/JCO.2002.01.133","article-title":"Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies","volume":"20","author":"Orlowski","year":"2002","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1053\/j.seminoncol.2013.07.007_bib55","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1038\/leu.2009.173","article-title":"Proteasome inhibitors in the treatment of multiple myeloma","volume":"23","author":"Shah","year":"2009","journal-title":"Leukemia"},{"issue":"5","key":"10.1053\/j.seminoncol.2013.07.007_bib56","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1182\/blood-2012-04-403733","article-title":"Proteasome inhibitors in multiple myeloma: 10 years later","volume":"120","author":"Moreau","year":"2012","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminoncol.2013.07.007_bib57","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1053\/j.seminhematol.2012.04.007","article-title":"Discovery and development of second-generation proteasome inhibitors","volume":"49","author":"Kirk","year":"2012","journal-title":"Semin Hematol"},{"issue":"6","key":"10.1053\/j.seminoncol.2013.07.007_bib58","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/blood-2012-10-459883","article-title":"Carfilzomib","volume":"121","author":"Kortuem","year":"2013","journal-title":"Blood"},{"issue":"9","key":"10.1053\/j.seminoncol.2013.07.007_bib59","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1182\/blood-2007-01-065888","article-title":"Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma","volume":"110","author":"Kuhn","year":"2007","journal-title":"Blood"},{"issue":"13","key":"10.1053\/j.seminoncol.2013.07.007_bib60","doi-asserted-by":"crossref","first-page":"6383","DOI":"10.1158\/0008-5472.CAN-06-4086","article-title":"Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome","volume":"67","author":"Demo","year":"2007","journal-title":"Cancer Res"},{"issue":"2","key":"10.1053\/j.seminoncol.2013.07.007_bib61","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/leu.2012.183","article-title":"The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects","volume":"27","author":"Hurchla","year":"2013","journal-title":"Leukemia"},{"issue":"9","key":"10.1053\/j.seminoncol.2013.07.007_bib62","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1158\/1078-0432.CCR-10-1950","article-title":"Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events","volume":"17","author":"Arastu-Kapur","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"22","key":"10.1053\/j.seminoncol.2013.07.007_bib63","doi-asserted-by":"crossref","first-page":"7085","DOI":"10.1158\/1078-0432.CCR-09-0822","article-title":"A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies","volume":"15","author":"O'Connor","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"17","key":"10.1053\/j.seminoncol.2013.07.007_bib64","doi-asserted-by":"crossref","first-page":"4830","DOI":"10.1158\/1078-0432.CCR-11-3007","article-title":"A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma","volume":"18","author":"Alsina","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"18","key":"10.1053\/j.seminoncol.2013.07.007_bib65","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2011-05-356063","article-title":"Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide","volume":"118","author":"Zhu","year":"2012","journal-title":"Blood"},{"issue":"11","key":"10.1053\/j.seminoncol.2013.07.007_bib66","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1038\/leu.2012.119","article-title":"Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide","volume":"26","author":"Lopez-Girona","year":"2012","journal-title":"Leukemia"},{"issue":"3","key":"10.1053\/j.seminoncol.2013.07.007_bib67","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.bbrc.2012.09.108","article-title":"Cereblon inhibits proteasome activity by binding to the 20S core proteasome subunit beta type 4","volume":"427","author":"Lee","year":"2012","journal-title":"Biochem Biophys Res Commun"},{"issue":"13","key":"10.1053\/j.seminoncol.2013.07.007_bib68","doi-asserted-by":"crossref","first-page":"11009","DOI":"10.1074\/jbc.M110.180208","article-title":"Evidence of a role for activation of Wnt\/beta-catenin signaling in the resistance of plasma cells to lenalidomide","volume":"286","author":"Bjorklund","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1053\/j.seminoncol.2013.07.007_bib69","first-page":"118","article-title":"Targeting the Wnt\/\u03b2-catenin signaling pathway and CD44-mediated adhesion as a rational approach to overcome lenalidomide resistance in multiple myeloma","author":"Bjorklund","year":"2011","journal-title":"Blood"},{"issue":"13","key":"10.1053\/j.seminoncol.2013.07.007_bib70","doi-asserted-by":"crossref","first-page":"3797","DOI":"10.1093\/emboj\/16.13.3797","article-title":"beta-catenin is a target for the ubiquitin-proteasome pathway","volume":"16","author":"Aberle","year":"1997","journal-title":"EMBO J"},{"issue":"5","key":"10.1053\/j.seminoncol.2013.07.007_bib71","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/leu.2011.303","article-title":"beta-catenin is dynamically stored and cleared in multiple myeloma by the proteasome-aggresome-autophagosome-lysosome pathway","volume":"26","author":"Sukhdeo","year":"2012","journal-title":"Leukemia"},{"issue":"24","key":"10.1053\/j.seminoncol.2013.07.007_bib72","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2012-03-414359","article-title":"An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and\/or refractory multiple myeloma","volume":"119","author":"Vij","year":"2012","journal-title":"Blood"},{"issue":"6","key":"10.1053\/j.seminoncol.2013.07.007_bib73","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/j.1365-2141.2012.09232.x","article-title":"An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and\/or refractory multiple myeloma who have been previously treated with bortezomib","volume":"158","author":"Vij","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminoncol.2013.07.007_bib74","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1186\/1471-2407-12-415","article-title":"Design and rationale of FOCUS (PX-171-011): A randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma (R\/R MM)","volume":"12","author":"Hajek","year":"2012","journal-title":"BMC Cancer"},{"issue":"21","key":"10.1053\/j.seminoncol.2013.07.007_bib75","first-page":"4036","article-title":"A phase 1b study of 30-minute infusion carfilzomib 20\/45 and 20\/56 mg\/m2 plus 40 mg weekly dexamethasone in patients with relapsed and\/or refractory (R\/R) multiple myeloma","volume":"120","author":"Badros","year":"2012","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"21","key":"10.1053\/j.seminoncol.2013.07.007_bib76","first-page":"947","article-title":"Phase II study of infusional carfilzomib in patients with relapsed or refractory multiple myeloma","volume":"120","author":"Lendvai","year":"2012","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"5","key":"10.1053\/j.seminoncol.2013.07.007_bib77","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","article-title":"Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study","volume":"12","author":"Moreau","year":"2011","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1053\/j.seminoncol.2013.07.007_bib78","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1158\/0008-5472.CAN-09-2766","article-title":"Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer","volume":"70","author":"Kupperman","year":"2010","journal-title":"Cancer Res"},{"issue":"16","key":"10.1053\/j.seminoncol.2013.07.007_bib79","doi-asserted-by":"crossref","first-page":"5311","DOI":"10.1158\/1078-0432.CCR-11-0476","article-title":"In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells","volume":"17","author":"Chauhan","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"19","key":"10.1053\/j.seminoncol.2013.07.007_bib80","doi-asserted-by":"crossref","first-page":"3958","DOI":"10.1182\/blood-2012-01-401794","article-title":"Investigational agent MLN9708\/2238 targets tumor-suppressor miR33b in MM cells","volume":"120","author":"Tian","year":"2012","journal-title":"Blood"},{"issue":"21","key":"10.1053\/j.seminoncol.2013.07.007_bib81","first-page":"301","article-title":"Investigational agent MLN9708, an oral proteasome inhibitor, in patients (pts) with relapsed and\/or refractory multiple myeloma (MM): results from the expansion cohorts of a phase 1 dose-escalation study","volume":"118","author":"Richardson","year":"2011","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"21","key":"10.1053\/j.seminoncol.2013.07.007_bib82","first-page":"816","article-title":"Weekly dosing of the investigational oral proteasome inhibitor MLN9708 in patients with relapsed and\/or refractory multiple myeloma: results from a phase 1 dose-escalation study","volume":"118","author":"Kumar","year":"2011","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"21","key":"10.1053\/j.seminoncol.2013.07.007_bib83","first-page":"332","article-title":"A phase 1\/2 study of weekly MLN9708, an investigational oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma (MM)","volume":"120","author":"Kumar","year":"2012","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"1","key":"10.1053\/j.seminoncol.2013.07.007_bib84","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/2162-3619-1-27","article-title":"Thalidomide and its analogues in the treatment of multiple myeloma","volume":"1","author":"Latif","year":"2012","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"10.1053\/j.seminoncol.2013.07.007_bib85","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1586\/ehm.12.62","article-title":"Immunomodulatory drugs in multiple myeloma","volume":"6","author":"Andhavarapu","year":"2013","journal-title":"Expert Rev Hematol"},{"issue":"2","key":"10.1053\/j.seminoncol.2013.07.007_bib86","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1517\/13543784.2013.749235","article-title":"Novel immunomodulatory compounds in multiple myeloma","volume":"22","author":"Saini","year":"2013","journal-title":"Expert Opin Investig Drugs"},{"issue":"3","key":"10.1053\/j.seminoncol.2013.07.007_bib87","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1124\/jpet.102.048496","article-title":"Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs","volume":"305","author":"Schafer","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"issue":"9","key":"10.1053\/j.seminoncol.2013.07.007_bib88","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1182\/blood.V96.9.2943","article-title":"Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy","volume":"96","author":"Hideshima","year":"2000","journal-title":"Blood"},{"issue":"16","key":"10.1053\/j.seminoncol.2013.07.007_bib89","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1200\/JCO.2004.10.052","article-title":"Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma","volume":"22","author":"Schey","year":"2004","journal-title":"J Clin Oncol"},{"issue":"30","key":"10.1053\/j.seminoncol.2013.07.007_bib90","doi-asserted-by":"crossref","first-page":"5008","DOI":"10.1200\/JCO.2009.23.6802","article-title":"Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma","volume":"27","author":"Lacy","year":"2009","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1053\/j.seminoncol.2013.07.007_bib91","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1038\/leu.2010.190","article-title":"Pomalidomide (CC4047) plus low dose dexamethasone (Pom\/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)","volume":"24","author":"Lacy","year":"2010","journal-title":"Leukemia"},{"issue":"11","key":"10.1053\/j.seminoncol.2013.07.007_bib92","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1182\/blood-2011-04-348896","article-title":"Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease","volume":"118","author":"Lacy","year":"2011","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2013.07.007_bib93","doi-asserted-by":"crossref","unstructured":"Leleu X, Attal M, Arnulf B, et al. Pomalidomide plus low dose dexamethasone is active and well tolerated in bortezomib and lenalidomide refractory multiple myeloma: IFM 2009-02. Blood. 2013.","DOI":"10.1182\/blood-2012-09-452375"},{"key":"10.1053\/j.seminoncol.2013.07.007_bib94","article-title":"Phase I study of pomalidomide MTD, safety and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib","author":"Richardson","year":"2012","journal-title":"Blood"},{"issue":"21","key":"10.1053\/j.seminoncol.2013.07.007_bib95","first-page":"4070","article-title":"Pomalidomide (POM) with low-dose dexamethasone (LoDEX) in patients with relapsed and refractory multiple myeloma (RRMM): outcomes based on prior treatment exposure","volume":"120","author":"Vij","year":"2012","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"21","key":"10.1053\/j.seminoncol.2013.07.007_bib96","article-title":"Pomalidomide in combination with low-dose dexamethasone: demonstrates a significant progression free survival and overall survival advantage, in relapsed\/refractory MM: a phase 3, multicenter, randomized, open-label study","volume":"120","author":"Dimopoulos","year":"2012","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"9","key":"10.1053\/j.seminoncol.2013.07.007_bib97","doi-asserted-by":"crossref","first-page":"919","DOI":"10.2217\/imt.12.82","article-title":"Monoclonal antibody-based immunotherapy for multiple myeloma","volume":"4","author":"Danylesko","year":"2012","journal-title":"Immunotherapy"},{"issue":"1","key":"10.1053\/j.seminoncol.2013.07.007_bib98","first-page":"22","article-title":"Therapeutic monoclonal antibodies for multiple myeloma: an update and future perspectives","volume":"1","author":"Yang","year":"2011","journal-title":"Am J Blood Res"},{"key":"10.1053\/j.seminoncol.2013.07.007_bib99","doi-asserted-by":"crossref","first-page":"924058","DOI":"10.1155\/2011\/924058","article-title":"Antibody-based therapies in multiple myeloma","volume":"2011","author":"Tai","year":"2011","journal-title":"Bone Marrow Res"},{"issue":"13","key":"10.1053\/j.seminoncol.2013.07.007_bib100","first-page":"4653","article-title":"Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence","volume":"9","author":"Trikha","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1053\/j.seminoncol.2013.07.007_bib101","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/j.ejca.2005.12.026","article-title":"Signalling and survival pathways in multiple myeloma","volume":"42","author":"Bommert","year":"2006","journal-title":"Eur J Cancer"},{"issue":"21","key":"10.1053\/j.seminoncol.2013.07.007_bib102","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1158\/1078-0432.CCR-07-1293","article-title":"Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma","volume":"13","author":"Voorhees","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1053\/j.seminoncol.2013.07.007_bib103","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1365-2141.2009.07647.x","article-title":"Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death","volume":"145","author":"Voorhees","year":"2009","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1053\/j.seminoncol.2013.07.007_bib104","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.1365-2141.2010.08533.x","article-title":"Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma","volume":"152","author":"Hunsucker","year":"2011","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1053\/j.seminoncol.2013.07.007_bib105","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1046\/j.1365-2141.1998.00835.x","article-title":"Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose-escalating study","volume":"102","author":"van Zaanen","year":"1998","journal-title":"Br J Haematol"},{"issue":"21","key":"10.1053\/j.seminoncol.2013.07.007_bib106","first-page":"3959","article-title":"Long-term safety in a phase 1 study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in patients with B-cell non-Hodgkin's lymphoma, multiple myeloma, or Castleman's disease","volume":"118","author":"Kurzrock","year":"2011","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminoncol.2013.07.007_bib107","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2012.12.010","article-title":"Complete remission achieved with single agent CNTO 328, an anti-IL-6 monoclonal antibody, in relapsed and refractory myeloma","author":"Chari","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1053\/j.seminoncol.2013.07.007_bib108","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.12266","article-title":"A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma","author":"Voorhees","year":"2013","journal-title":"Br J Haematol"},{"issue":"Suppl","key":"10.1053\/j.seminoncol.2013.07.007_bib109","article-title":"Phase II, randomized, double blind, placebo-controlled study comparing siltuximab plus bortezomib versus bortezomib alone in pts with relapsed\/refractory multiple myeloma","volume":"30","author":"Orlowski","year":"2012","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1053\/j.seminoncol.2013.07.007_bib110","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1182\/blood-2007-08-107292","article-title":"Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu","volume":"112","author":"Tai","year":"2008","journal-title":"Blood"},{"issue":"9","key":"10.1053\/j.seminoncol.2013.07.007_bib111","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1158\/1078-0432.CCR-07-4246","article-title":"CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma","volume":"14","author":"Hsi","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1053\/j.seminoncol.2013.07.007_bib112","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1158\/1535-7163.MCT-09-0483","article-title":"Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma","volume":"8","author":"van Rhee","year":"2009","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"10.1053\/j.seminoncol.2013.07.007_bib113","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1182\/blood-2011-06-360552","article-title":"A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma","volume":"120","author":"Zonder","year":"2012","journal-title":"Blood"},{"issue":"16","key":"10.1053\/j.seminoncol.2013.07.007_bib114","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1200\/JCO.2011.37.7069","article-title":"Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed\/refractory multiple myeloma","volume":"30","author":"Jakubowiak","year":"2012","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"10.1053\/j.seminoncol.2013.07.007_bib115","article-title":"Phase I trial of elotuzumab, lenalidomide, and low-dose dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"29","author":"Lonial","year":"2011","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1053\/j.seminoncol.2013.07.007_bib116","first-page":"202","article-title":"A phase 2 study of elotuzumab (Elo) in combination with lenalidomide and low-dose dexamethasone (Ld) in patients (pts) with relapsed\/refractory multiple myeloma (R\/R MM): updated results","volume":"120","author":"Richardson","year":"2012","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"9","key":"10.1053\/j.seminoncol.2013.07.007_bib117","doi-asserted-by":"crossref","first-page":"e7258","DOI":"10.1371\/journal.pone.0007258","article-title":"Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT","volume":"4","author":"Dubreuil","year":"2009","journal-title":"PLoS One"},{"issue":"6","key":"10.1053\/j.seminoncol.2013.07.007_bib118","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1111\/j.1939-1676.2008.0190.x","article-title":"Masitinib is safe and effective for the treatment of canine mast cell tumors","volume":"22","author":"Hahn","year":"2008","journal-title":"J Vet Intern Med"},{"issue":"13","key":"10.1053\/j.seminoncol.2013.07.007_bib119","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1016\/j.ejca.2009.05.010","article-title":"Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and\/or metastatic solid cancers","volume":"45","author":"Soria","year":"2009","journal-title":"Eur J Cancer"},{"issue":"8","key":"10.1053\/j.seminoncol.2013.07.007_bib120","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.ejca.2010.02.014","article-title":"Phase II study of oral masitinib mesilate in imatinib-naive patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST)","volume":"46","author":"Le Cesne","year":"2010","journal-title":"Eur J Cancer"},{"issue":"12","key":"10.1053\/j.seminoncol.2013.07.007_bib121","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/ajh.21894","article-title":"Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study","volume":"85","author":"Paul","year":"2010","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1053\/j.seminoncol.2013.07.007_bib122","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1600-0609.2012.01761.x","article-title":"Mast cell leukemia: identification of a new c-Kit mutation, dup(501-502), and response to masitinib, a c-Kit tyrosine kinase inhibitor","volume":"89","author":"Georgin-Lavialle","year":"2012","journal-title":"Eur J Haematol"},{"issue":"5-6","key":"10.1053\/j.seminoncol.2013.07.007_bib123","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3109\/10428199609052429","article-title":"C-kit ligand (SCF) in human multiple myeloma cells","volume":"20","author":"Lemoli","year":"1996","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminoncol.2013.07.007_bib124","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.1038\/bcj.2012.37","article-title":"The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: prognostic implications and current clinical strategies","volume":"2","author":"Kalff","year":"2012","journal-title":"Blood Cancer J"},{"issue":"13","key":"10.1053\/j.seminoncol.2013.07.007_bib125","first-page":"1367","article-title":"Signal transduction of interleukin-6 involves tyrosine phosphorylation of multiple cytosolic proteins and activation of Src-family kinases Fyn, Hck, and Lyn in multiple myeloma cell lines","volume":"25","author":"Hallek","year":"1997","journal-title":"Exp Hematol"},{"issue":"3","key":"10.1053\/j.seminoncol.2013.07.007_bib126","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.bbrc.2010.01.038","article-title":"A novel signaling pathway associated with Lyn, PI 3-kinase and Akt supports the proliferation of myeloma cells","volume":"392","author":"Iqbal","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"10.1053\/j.seminoncol.2013.07.007_bib127","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1182\/blood-2007-10-116590","article-title":"Validation of PDGFRbeta and c-Src tyrosine kinases as tumor\/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib","volume":"112","author":"Coluccia","year":"2008","journal-title":"Blood"},{"issue":"12","key":"10.1053\/j.seminoncol.2013.07.007_bib128","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1038\/sj.bjc.6604388","article-title":"Antitumour and antiangiogenic effects of Aplidin in the 5TMM syngeneic models of multiple myeloma","volume":"98","author":"Caers","year":"2008","journal-title":"Br J Cancer"},{"issue":"13","key":"10.1053\/j.seminoncol.2013.07.007_bib129","doi-asserted-by":"crossref","first-page":"5216","DOI":"10.1158\/0008-5472.CAN-07-5725","article-title":"Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo","volume":"68","author":"Mitsiades","year":"2008","journal-title":"Cancer Res"},{"issue":"12","key":"10.1053\/j.seminoncol.2013.07.007_bib130","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1158\/1078-0432.CCR-10-0469","article-title":"Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma","volume":"16","author":"Mateos","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1053\/j.seminoncol.2013.07.007_bib131","doi-asserted-by":"crossref","first-page":"4053","DOI":"10.1182\/blood-2005-08-3434","article-title":"Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells","volume":"107","author":"Hideshima","year":"2006","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminoncol.2013.07.007_bib132","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s10549-006-9232-x","article-title":"Proteasome inhibitors induce a p38 mitogen-activated protein kinase (MAPK)-dependent anti-apoptotic program involving MAPK phosphatase-1 and Akt in models of breast cancer","volume":"100","author":"Shi","year":"2006","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"10.1053\/j.seminoncol.2013.07.007_bib133","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/j.1365-2141.2007.06714.x","article-title":"Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells","volume":"138","author":"Hideshima","year":"2007","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1053\/j.seminoncol.2013.07.007_bib134","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1182\/blood-2006-04-016824","article-title":"Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts","volume":"109","author":"Gajate","year":"2007","journal-title":"Blood"},{"issue":"16","key":"10.1053\/j.seminoncol.2013.07.007_bib135","doi-asserted-by":"crossref","first-page":"5090","DOI":"10.1158\/1078-0432.CCR-08-0016","article-title":"Perifosine synergistically enhances TRAIL-induced myeloma cell apoptosis via up-regulation of death receptors","volume":"14","author":"David","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1053\/j.seminoncol.2013.07.007_bib136","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/j.1365-2141.2012.09173.x","article-title":"Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed\/refractory multiple myeloma: a phase I Multiple Myeloma Research Consortium study","volume":"158","author":"Jakubowiak","year":"2012","journal-title":"Br J Haematol"},{"issue":"32","key":"10.1053\/j.seminoncol.2013.07.007_bib137","doi-asserted-by":"crossref","first-page":"4243","DOI":"10.1200\/JCO.2010.33.9788","article-title":"Perifosine plus bortezomib and dexamethasone in patients with relapsed\/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I\/II trial","volume":"29","author":"Richardson","year":"2011","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1053\/j.seminoncol.2013.07.007_bib138","first-page":"73","article-title":"A CD38 monoclonal antibody in patients with multiple myeloma - data from a dose-escalation phase I\/II study","volume":"120","author":"Plesner","year":"2012","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"21","key":"10.1053\/j.seminoncol.2013.07.007_bib139","first-page":"449","article-title":"The novel KSP inhibitor ARRY-520 is active both with and without low-dose dexamethasone in patients with multiple myeloma refractory to bortezomib and lenalidomide: results from a phase 2 study","volume":"120","author":"Shah","year":"2012","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"21","key":"10.1053\/j.seminoncol.2013.07.007_bib140","first-page":"4082","article-title":"Phase 1 study of the novel kinesin spindle protein inhibitor ARRY-520 + carfilzomib in patients with relapsed and\/or refractory multiple myeloma","volume":"120","author":"Shah","year":"2012","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"19","key":"10.1053\/j.seminoncol.2013.07.007_bib141","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","article-title":"Lenalidomide after stem-cell transplantation for multiple myeloma","volume":"366","author":"McCarthy","year":"2012","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1053\/j.seminoncol.2013.07.007_bib142","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","article-title":"Lenalidomide maintenance after stem-cell transplantation for multiple myeloma","volume":"366","author":"Attal","year":"2012","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1053\/j.seminoncol.2013.07.007_bib143","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1056\/NEJMoa1112704","article-title":"Continuous lenalidomide treatment for newly diagnosed multiple myeloma","volume":"366","author":"Palumbo","year":"2012","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1053\/j.seminoncol.2013.07.007_bib144","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1182\/blood-2012-05-427815","article-title":"Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial","volume":"120","author":"Mateos","year":"2012","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.seminoncol.2013.07.007_bib145","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2165\/11585930-000000000-00000","article-title":"The role of bortezomib, thalidomide and lenalidomide in the management of multiple myeloma: an overview of clinical and economic information","volume":"29","author":"Messori","year":"2011","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"10.1053\/j.seminoncol.2013.07.007_bib146","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1586\/era.12.42","article-title":"Novel anticancer agents for multiple myeloma: a review of the evidence for their therapeutic and economic value","volume":"12","author":"Gaultney","year":"2012","journal-title":"Expert Rev Anticancer Ther"},{"issue":"1","key":"10.1053\/j.seminoncol.2013.07.007_bib147","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/jcpt.12020","article-title":"Real-world health care costs of relapsed\/refractory multiple myeloma during the era of novel cancer agents","volume":"38","author":"Gaultney","year":"2013","journal-title":"J Clin Pharm Ther"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775413001310?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775413001310?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T23:55:27Z","timestamp":1596671727000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775413001310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":147,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S0093775413001310"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2013.07.007","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]}}}